Table 3.
Antiviral activity of rIFN-λ1 in combination with various classes of HCV replication inhibitors
| Drug combination (estimated EC50s) | Ratio of indicated inhibitor to rIFN-λ1 | CI (95% confidence interval) |
Overall result | ||
|---|---|---|---|---|---|
| 50% effective level | 75% effective level | 90% effective level | |||
| rIFN-α–rIFN-λ1 (18 IU/ml-0.3 ng/ml) | 9:1 | 0.94 (0.78, 1.09) | 0.89 (0.68, 1.10) | 0.85 (0.54, 1.16) | Additivity/synergy |
| 18:5 | 0.93 (0.78, 1.08) | 0.82 (0.64, 1.00) | 0.73 (0.47, 0.99) | ||
| 45:2 | 0.82 (0.70, 0.95) | 0.64 (0.50, 0.78) | 0.51 (0.33, 0.68) | ||
| ASV–rIFN-λ1 (1.3 nM-0.4 ng/ml) | 7:5 | 0.98 (0.82, 1.15) | 0.82 (0.63, 1.01) | 0.72 (0.46, 0.99) | Additivity/synergy |
| 14:5 | 0.97 (0.81, 1.14) | 0.85 (0.64, 1.05) | 0.76 (0.48, 1.05) | ||
| 7:2 | 0.88 (0.74, 1.02) | 0.75 (0.58, 0.92) | 0.67 (0.43, 0.91) | ||
| DCV–rIFN-λ1 (5 nM-3.9 ng/ml) | 1:310 | 0.99 (0.94, 1.04) | 0.93 (0.87, 0.99) | 0.88 (0.78, 0.98) | Additivity/synergy |
| 1:775 | 0.93 (0.87, 0.98) | 0.92 (0.84, 0.99) | 0.92 (0.81, 1.03) | ||
| 1:124 | 1.06 (1.00, 1.12) | 1.06 (0.97, 1.16) | 1.07 (0.93, 1.22) | ||
| NS5B I–rIFN-λ1 (3.6 nM-9.8 ng/ml) | 100:93 | 1.07 (0.98, 1.17) | 1.12 (0.99, 1.25) | 1.18 (0.97, 1.39) | Additivity |
| 40:93 | 1.08 (0.99, 1.17) | 1.05 (0.93, 1.17) | 1.03 (0.86, 1.20) | ||
| 250:93 | 0.91 (0.83, 1.00) | 1.03 (0.90, 1.17) | 1.18 (0.93, 1.42) | ||